Short Summary
This appeal before the Telangana High Court concerned an infringement suit filed by Novartis Ag against Msn Laboratories Pvt. Ltd regarding patent IN 229051, which covers a specific Valsartan/Sacubitril combination drug. The respondents (Novartis) had secured an interim injunction based on prima facie evidence of infringement due to the appellant's (Msn Labs) manufacturing approval for a similar formulation. The court examined the statutory provisions of the Patents Act and CPC, ultimately dismissing the appeal and upholding the injunction granted in favor of Novartis.
Detailed Summary
In the high-stakes world of pharmaceuticals, the line between a legitimate generic launch and patent infringement can mean hundreds of crores in revenue, regulatory headaches, and years of litigation. When a generic player moves first with a manufacturing approval for a drug still under patent, the patent holder's most powerful weapon is often not a final judgment, but an interim injunction granted at the very outset of the dispute. The recent clash between Novartis AG and MSN Laboratories before the Telangana High Court is a textbook example of how courts evaluate these urgent requests, and why the burden of proof at the prima facie stage can be decisive.
Novartis AG, the global pharmaceutical innovator, holds Indian Patent IN 229051, which covers a specific Valsartan/Sacubitril combination drug. This combination is used in the treatment of heart failure and represents a significant commercial product in Novartis's portfolio. MSN Laboratories Pvt. Ltd, an Indian generic pharmaceutical manufacturer, secured a manufacturing approval for a formulation that Novartis alleged was covered by the claims of its patent. Novartis responded by filing an infringement suit and seeking urgent interim relief to prevent MSN from manufacturing and selling the allegedly infringing product. Based on the prima facie evidence presented, the trial court granted an interim injunction in favor of Novartis, restraining MSN Labs from proceeding with its launch. Dissatisfied with this order, MSN Laboratories approached the Telangana High Court in appeal, challenging the grant of the injunction.
MSN Laboratories argued that the interim injunction was improperly granted, contending that the court below had erred in finding a prima facie case of infringement. MSN also raised counterclaims challenging the validity of Novartis's patent, arguing that the patent itself ought to be scrutinized before any restraint could be imposed on its manufacturing activities. On the other side, Novartis maintained that the formulation being manufactured by MSN Labs fell squarely within the scope of its patent claims, and that the balance of convenience and the risk of irreparable harm to its patent rights justified the injunction. Novartis emphasized that allowing MSN to launch during the pendency of the suit would cause irreversible damage to its exclusive rights under the Patents Act. The legal friction centered on whether the threshold for an interim injunction had been properly met, and whether the existence of counterclaims should have changed the calculus at the interim stage.
The Telangana High Court, after examining the relevant provisions of the Patents Act and the Code of Civil Procedure, dismissed MSN Laboratories' appeal and upheld the interim injunction granted in favor of Novartis. The court found that Novartis had successfully established a prima facie case of infringement based on the materials placed before it at the interim stage. The court reasoned that the existence of counterclaims regarding the validity of the patent did not, by itself, defeat the grant of an interim injunction, since the final merits of both the infringement suit and the counterclaims would have to be decided only after full evidence was adduced by both parties. By upholding the injunction, the court reaffirmed that the interim stage is concerned with the appearance of right and the prevention of irreparable injury, not with the final adjudication of complex patent validity questions.
For founders, startup leaders, and IP professionals in the pharmaceutical and innovation-driven sectors, this case carries a clear and practical lesson: do not underestimate the importance of the prima facie threshold in patent litigation. If you are a generic manufacturer considering a launch, a manufacturing approval alone does not shield you from an interim injunction if the patent holder can demonstrate a credible case of infringement on the face of the record. Conversely, if you are a patent holder, this case confirms that securing early interim relief is a viable and powerful strategy
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Telangana High Court. Understanding the court's reasoning in Msn Laboratories Pvt. Ltd vs Novartis Ag is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
The North Face Apparel CorpvsController of Patents and Designs
The North Face Apparel Corp challenged the Controller of Patents' refusal of its patent application (No. 202147026139) titled 'Systems and Methods for End-to-End Article Management' before the Madras High Court under Section 117A of the Patents Act, 1970. The Controller had rejected the application citing lack of inventive step over prior art documents D21-D24. The Court held that the Controller erred by dissecting the claims into isolated elements rather than assessing the invention as a whole, and overlooked the use of spectrophotometer and invisible markers for tracking the manufacturing process, which were not disclosed in the cited prior art. The appeal was allowed and the Controller was directed to grant the patent.
Aventose Energy Private LimitedvsThe Assistant Controller of Patents & Designs, Patent Office Chennai
Aventose Energy Private Limited appealed under Section 117A of the Patents Act, 1970 against the refusal of its patent application (No. 202141019671) for a 'System and Method for Operating Automobiles with an Electric Drivetrain' featuring safe mode activation upon fault detection. The Madras High Court found that the Assistant Controller had contradicted the First Examination Report (which accepted novelty) by subsequently holding the invention lacked novelty without giving the applicant an opportunity to be heard. The court further held that the Controller improperly conflated novelty with inventive step under Section 2(1)(ja) and failed to properly analyze the claims against prior art documents D1–D4.
Apex Laboratories Pvt LtdvsElder Lifescience and Ambico Ayurvedic Health Care
Apex Laboratories Pvt Ltd, the prior adopter and registered proprietor of the trademark ZINCOVIT (TM No. 487453 in Class 5) since 1988, sought interim injunction against Elder Lifescience and Ambico Ayurvedic Health Care for using the deceptively similar mark NEO ZINCOVIT. The applicant also claimed copyright infringement of its registered artistic works (A-108878/2014) covering colour scheme, get-up, and layout. The Madras High Court was satisfied that the respondents were attempting to piggyback on the applicant's goodwill and granted interim injunctions on all three applications covering trademark infringement, copyright infringement, and passing off.
Radico Khaitan LimitedvsPicadilly Agro Industries Limited
This Special Leave Petition arose from a judgment dated 29-05-2026 in CS No. 8/2025 passed by the District Judge, Karnal, Haryana, concerning a trademark dispute over the marks 'Cashmere' and 'Kashmyr' used in relation to beer and vodka. The Supreme Court noted that a First Appeal (FAO-COM-11-2026) was already pending before the Division Bench of the Punjab and Haryana High Court, listed for 28.10.2026. The Court disposed of the SLP without adjudicating it on merits, requesting the High Court to pass an appropriate order regarding the ad interim injunction on the scheduled date.
Maharaja Agrasen Technical Educational Society (Regd.)vsMaharaja Agrasen Himalayan Garhwal University
The plaintiff, Maharaja Agrasen Technical Educational Society, filed a suit for permanent injunction against the defendant, Maharaja Agrasen Himalayan Garhwal University, alleging infringement and passing off regarding the use of the words 'Maharaja Agrasen' in the defendant's name. The Delhi High Court had previously granted a restraint order on 10.07.2026. During the pendency of the suit, the parties arrived at a settlement dated 14.09.2026, under which the defendant agreed to change its name through a statutory amendment while being permitted limited transitional use of its existing name. The court recorded the settlement, modified the interim order accordingly, and listed the matter for compliance reporting on 13.07.2027.
Varahi Diamonds And Finance LimitedvsSahil Vinay Mehra Trading As Mehra Sons Jewellers & Anr.
This is a commercial suit filed by Varahi Diamonds And Finance Limited against Sahil Vinay Mehra Trading As Mehra Sons Jewellers & Anr. before the Delhi High Court. The order is primarily procedural, dealing with the registration of the plaint, issuance of summons, directions for filing pleadings, and an interim injunction application. The matter was referred to mediation, with parties directed to appear before the Delhi High Court Mediation and Conciliation Centre.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.